Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 6)
Latest Information Update: 21 May 2026
At a glance
- Drugs Zenagamtide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms AMAZE 6
- Sponsors Novo Nordisk
Most Recent Events
- 15 May 2026 Planned End Date changed from 17 Jul 2028 to 14 Aug 2028.
- 15 May 2026 Planned primary completion date changed from 19 Jun 2028 to 14 Aug 2028.
- 15 May 2026 Status changed from not yet recruiting to recruiting.